Small peptide inhibitor from the sequence of RUNX3 disrupts PAK1–RUNX3 interaction and abrogates its phosphorylation-dependent oncogenic function
- 12 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (34), 5327-5341
- https://doi.org/10.1038/s41388-021-01927-x
Abstract
P21 Activated Kinase 1 (PAK1) is an oncogenic serine/threonine kinase known to play a significant role in the regulation of cytoskeleton and cell morphology. Runt-related transcription factor 3 (RUNX3) was initially known for its tumor suppressor function, but recent studies have reported the oncogenic role of RUNX3 in various cancers. Previous findings from our laboratory provided evidence that Threonine 209 phosphorylation of RUNX3 acts as a molecular switch in dictating the tissue-specific dualistic functions of RUNX3 for the first time. Based on these proofs and to explore the translational significance of these findings, we designed a small peptide (RMR) from the protein sequence of RUNX3 flanking the Threonine 209 phosphorylation site. The selection of this specific peptide from multiple possible peptides was based on their binding energies, hydrogen bonding, docking efficiency with the active site of PAK1 and their ability to displace PAK1–RUNX3 interaction in our prediction models. We found that this peptide is stable both in in vitro and in vivo conditions, not toxic to normal cells and inhibits the Threonine 209 phosphorylation in RUNX3 by PAK1. We also tested the efficacy of this peptide to block the RUNX3 Threonine 209 phosphorylation mediated tumorigenic functions in in vitro cell culture models, patient-derived explant (PDE) models and in in vivo tumor xenograft models. These results proved that this peptide has the potential to be developed as an efficient therapeutic molecule for targeting RUNX3 Threonine 209 phosphorylation-dependent tumor phenotypes.This publication has 64 references indexed in Scilit:
- A Cancer Specific Cell-Penetrating Peptide, BR2, for the Efficient Delivery of an scFv into Cancer CellsPLOS ONE, 2013
- PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptidesNucleic Acids Research, 2012
- Clonidine Improved Laboratory-Measured Decision-Making Performance in Abstinent Heroin AddictsPLOS ONE, 2012
- Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticProceedings of the National Academy of Sciences of the United States of America, 2010
- Src Kinase Phosphorylates RUNX3 at Tyrosine Residues and Localizes the Protein in the CytoplasmOnline Journal of Public Health Informatics, 2010
- CXCL10 expression and prognostic significance in stage II and III colorectal cancerMolecular Biology Reports, 2009
- RUNX3 Has an Oncogenic Role in Head and Neck CancerPLOS ONE, 2009
- GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular SimulationJournal of Chemical Theory and Computation, 2008
- I-TASSER server for protein 3D structure predictionBMC Bioinformatics, 2008
- Evaluation of time profile reconstruction from complex two-color microarray designsBMC Bioinformatics, 2008